# Abeona Therapeutics Inc. (ABEO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.00, market value $343 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Abeona Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 59.0×**. Each dollar of revenue is priced at 59.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -23.8%** (5-yr avg -94.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 44.7%**. 44.7% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -70.1%**. Return on all capital, debt included, is -70.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 32.4%**. Each dollar of assets produces 32.4% of profit.

## Growth
- **EPS growth (1 yr): 165.2%**. Earnings per share rose 165.2%.

## Financial health
- **Debt to equity: 0.13**. Debt is 0.13 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 3.11**. A Z-score of 3.11 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Abeona Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Abeona Therapeutics Inc.; the consensus is strong_buy, with an average price target of $18.86 (+214% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -12.5%** (YTD 13.9%, 3-mo 9.9%). The shares are down 12.5% over twelve months including dividends.
- **From 52-week high: -21.6%** (50.0% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 1.42** (volatility 54%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABEO · Page: https://foliofundamentals.com/stocks/abeo

Not investment advice.